Effect of inhaled ciclesonide in adult patients with asthma (BY9010/M1-125)

Study identifier:BY9010/M1-125

ClinicalTrials.gov identifier:NCT00546520

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A 3-period double-blind, cross-over study on the onset of action of inhaled ciclesonide (7 days of 400 mcg sid versus 800 mcg bid versus placebo) on airway responsiveness to adenosine monophosphate (AMP), sputum eosinophiles and exhaled breath nitric oxide (NO) in patients with asthma

Medical condition

asthma

Phase

Phase 3

Healthy volunteers

No

Study drug

Ciclesonide

Sex

All

Actual Enrollment

21

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 01 Apr 2002
Primary Completion Date: 01 Jun 2002
Study Completion Date: 01 Jun 2002

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Prevention

Verification:

Verified 01 Feb 2017 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria